VIDA Diagnostics
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $300k | Early VC | |
N/A | $500k | Debt | |
$2.5m | Early VC | ||
$5.1m | Series B | ||
Total Funding | €7.2m |
Related Content
Recent News about VIDA Diagnostics
EditVIDA Diagnostics operates in the healthcare sector, specializing in advanced imaging solutions for respiratory diseases. The company leverages artificial intelligence (AI) to provide precise and personalized care for patients with lung conditions such as lung cancer, emphysema, asthma, and interstitial lung disease. VIDA's core products include LungPrint Insights, LungPrint Assist, and LungPrint Discovery, which offer comprehensive quantitative CT lung information and state-of-the-art reports for physicians. These solutions help in reducing procedural costs and improving patient outcomes. VIDA's services are available in the USA, EU, Canada, and Australia, and the company also supports pulmonary device and pharmaceutical vendors in clinical trials through its ISO 13485 certified core lab. The business model revolves around selling software and services to healthcare providers and clinical trial sponsors, generating revenue through product sales and service fees.
Keywords: AI-driven, imaging solutions, lung disease, quantitative CT, respiratory care, clinical efficiency, personalized care, healthcare sector, clinical trials, ISO 13485.